Bray, F, Ferlay, J, Soerjomataram, I,Siegel, R L, Torre, L A, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.
Dische, S, Saunders, M, Barrett, A. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123–136.
Bentzen, S M, Saunders, M I, Dische, S. Repair half-times estimated from observations of treatment-related morbidity after CHART. Radiother Oncol 1999; 53: 219–226.
Bentzen, S M, Saunders, M I, Dische, S. Radiotherapy related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduce from the CHART trial. Radiother Oncol 2001; 60: 123–135.
Landuyt, W, Fowler, J, Ruifrokb, A, Stiiben, G, van der Kogeld, A, van der Schuerena, E. Kinetics of repair in the spinal cord of the rat. Radiother Oncol 1997;45 (1): 55–62.
Overgaard, J, Hansen, H S, Specht, L. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomisedcontrolled trial. Lancet 2003; 362: 933–940.
Bourhis, J, Lapeyre, M, Tortochaux, J. Phase III randomized trial of very accelerated compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006; 24: 2873–2878.
Fowler, J F, Harari, P. Confirmation of improved local-regional control with altered fractionation in head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48: 3–6.
Withers, H R, Peters, L J. Transmutability of dose and time. Commentary on the first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 1–2.
Hall, E. Radiobiology for the Radiologist, 7th edition. Philadelphia: Wolters Kluwer, 2012: 401–403.
Denis, F, Garaud, P, Bardet, E. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69–76.
Brizel, D M, Albers, M E, Fisher, S R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798–1804.
Bernier, J, Domenge, C, Ozsahin, M. Postoperative irradiation with or without concomitant chemotherapy for locallyadvanced head and neck cancer. N Engl J Med 2004; 350: 1945–1952.
Semrau, R, Mueller, R P, Stuetzer, H. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5 fluorouracil: updated results of a randomized multicentric trial in advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 1308–1316.
Budach, V, Stuschke, M, Budach, W. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycinis more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J ClinOncol 2005; 23: 1125–1135.
Pignon, J P, Bourhis, J, Domenge, C, Designé, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949–955.
Pignon, J P, le Maître, A, Maillard, E, Bourhis, J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.
Kasibhatla, M, Kirkpatrick, J P, Brizel, D M. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2007; 68: 1491–1495.
Fowler, J. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2008; 71: 326–329.
Fowler, J. Practical time-dose evaluation, or how to stop worrying and love LQ. In: Levitt, SH, Purdy, JA, Perez, CA, Poortmans, P (eds). Technical Basis of Radiation Therapy, 5th revised edition. Heidelberg: Springer-Verlag, 2012: 9–46.
Overgaard, J, Hansen, H S, Specht, L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 & 7 randomized control trial. Lancet 2003; 362: 933–940.
Benghiat, H, Sanghera, P, Cashmore, J, Hodson, J, Mehanna, H, Simmons, R, et al. Four week hypofractionated accelerated intensity modulated radiotherapy and synchronous carboplatin or cetuximab in biologically staged oropharyngeal carcinoma. Cancer Clin Oncol 2014; 3 (2). doi: 10.5539/cco.v3n2p1
Chan, A K., Sanghera, P, Choo, B A, et al. Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 2011; 23 (1): 34–39.
Meduri, B, D’Angelo, E, Barbieri, P, et al. EP-1089: accelerated hypofractionated IMRT-IGRT and concurrent chemotherapy in oropharyngeal cancer. Radiother Oncol 2016; 119: S524.
Sanghera, P, McConkey, C, Ho, K F, Glaholm, J, Hartley, A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007; 67: 1342–1351.